Vanguard Group Inc Biocryst Pharmaceuticals Inc Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 20,544,248 shares of BCRX stock, worth $172 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,544,248
Previous 21,659,765
5.15%
Holding current value
$172 Million
Previous $162 Million
13.31%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
202MCall Options Held
930KPut Options Held
553K-
Black Rock Inc. New York, NY20MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$71 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$70.7 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$47.7 Million0.09% of portfolio
-
Ubs Group Ag5.61MShares$46.9 Million0.01% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.55B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...